

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/378498172>

Self-reported side effects of COVID-19 vaccines among the public

Article in *Journal of Pharmaceutical Policy and Practice* · February 2024

DOI: 10.1080/20523211.2024.2308617

CITATIONS

0

READS

67

6 authors, including:



Mahmathi Karuppannan

Universiti Teknologi MARA

79 PUBLICATIONS 167 CITATIONS

SEE PROFILE



L C Ming

Sunway University

505 PUBLICATIONS 9,718 CITATIONS

SEE PROFILE



Mohd Shahezwan Abd Wahab

Universiti Teknologi MARA

48 PUBLICATIONS 292 CITATIONS

SEE PROFILE



Zakiah Mohd Noordin

Universiti Teknologi MARA

8 PUBLICATIONS 14 CITATIONS

SEE PROFILE



Self-reported side effects of COVID-19 vaccines among the public

Mahmathi Karuppannan, Long Chiau Ming, Mohd Shahezwan Abd Wahab, Zakiah Mohd Noordin, Shermaine Yee & Andi Hermansyah

To cite this article: Mahmathi Karuppannan, Long Chiau Ming, Mohd Shahezwan Abd Wahab, Zakiah Mohd Noordin, Shermaine Yee & Andi Hermansyah (2024) Self-reported side effects of COVID-19 vaccines among the public, Journal of Pharmaceutical Policy and Practice, 17:1, 2308617, DOI: [10.1080/20523211.2024.2308617](https://doi.org/10.1080/20523211.2024.2308617)

To link to this article: <https://doi.org/10.1080/20523211.2024.2308617>



© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group



View supplementary material [↗](#)



Published online: 27 Feb 2024.



Submit your article to this journal [↗](#)



Article views: 287



View related articles [↗](#)



View Crossmark data [↗](#)









RESEARCH ARTICLE



OPEN ACCESS



Self-reported side effects of COVID-19 vaccines among the public

Mahmathi Karupppannan ^{a,b}, Long Chiau Ming ^{c,d,e},
Mohd Shahezwan Abd Wahab ^{a,b}, Zakiah Mohd Noordin ^{a,b},
Shermaine Yee ^f and Andi Hermansyah ^c


^aDepartment of Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA Cawangan Selangor, Bandar Puncak Alam, Malaysia; ^bCardiology Therapeutics Research Group, Faculty of Pharmacy, Universiti Teknologi MARA Cawangan Selangor, Puncak Alam Campus, Bandar Puncak Alam, Malaysia; ^cDepartment of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia; ^dSchool of Medical and Life Sciences, Sunway University, Sunway City, Malaysia; ^ePAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei; ^fFaculty of Medicine, Qest International University, Ipoh, Malaysia


ABSTRACT

Background: The safety, side effects and efficacy profile of COVID-19 vaccines remain subjects of ongoing concern among the public in Malaysia. The aim of this study was to determine the types of adverse effects following immunisation with COVID-19 vaccines and the differences based on various types of COVID-19 vaccines to raise public awareness and reduce vaccine hesitancy among the public.

Methods: A total of 901 Malaysian adults (≥ 18 years) who received various COVID-19 vaccines were selected to participate in our cross-sectional study through an online survey between December 2021 and January 2022.

Results: A total of 814 (90.3%) of the participants reported ≥ 1 side effect following COVID-19 immunisation. Of these, the predominant symptoms were swelling at the injection site ($n = 752$, 83.5%), headache ($n = 638$, 70.8%), pain or soreness at the injection site ($n = 628$, 69.7%), fatigue or tiredness ($n = 544$, 60.4%), muscle weakness ($n = 529$, 58.7%) and diarrhea ($n = 451$, 50.1%). Recipients of the Pfizer-BioNTech (Comirnaty[®]) vaccine reported the

CONTACT Mahmathi Karupppannan  mahmathi@uitm.edu.my  Department of Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA Cawangan Selangor, Puncak Alam Campus, Bandar Puncak Alam, Selangor 42300, Malaysia; Cardiology Therapeutics Research Group, Faculty of Pharmacy, Universiti Teknologi MARA Cawangan Selangor, Puncak Alam Campus, Bandar Puncak Alam, Selangor 42300, Malaysia; Andi Hermansyah  andi-h@ff.unair.ac.id  Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia; Long Chiau Ming  chiaumingl@sunway.edu.my  Department of Medical Sciences, School of Medical and Life Sciences, Sunway University, Sunway City 47500, Malaysia

 Supplemental data for this article can be accessed online at <https://doi.org/10.1080/20523211.2024.2308617>.

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

highest number of adverse effects ($n = 355$, 43.6%), followed by mixed COVID-19 vaccines ($n = 254$, 31.2%), the Oxford-AstraZeneca (ChAdOx1-® [recombinant]) vaccine ($n = 113$, 13.9%) and the Sinovac (CoronaVac®) vaccine ($n = 90$, 11.1%). The study showed that individuals who reported significantly more side effects were of elderly age, female gender and high educational level [P value < 0.05]. Mixed COVID-19 vaccine recipients also reported significantly more local and systemic symptoms after the first dose and third dose when compared with other single vaccine recipients.

Conclusion: This study demonstrated the types of self-reported adverse effects following immunisation with single and mixed COVID-19 vaccines. These findings may provide the side effects of different COVID-19 vaccines with the hope of educating the public on the safety profiles of these vaccines and reducing vaccine hesitancy among the public.

KEYWORDS Side (adverse) effect; COVID-19; vaccine hesitancy; mixed vaccine; single vaccine; communicable diseases; infectious disease

1. Introduction

Coronavirus Disease 2019 (COVID-19) has continued to be a significant threat to global public health since its first large-scale outbreak in December 2019. The combined discovery of its genetic sequence, adjuvants and vectors not only unravelled mysteries of this deadly virus but also triggered intense world-wide research and development of COVID-19 vaccines and therapeutic strategies at an unprecedented rate. Various new drugs and medical products without full Food and Drug Administration (FDA) approval were introduced to the public during the COVID-19 public health emergency. Currently, medications such as antiviral drugs, neutral antibody therapies, immunomodulators and cell and gene therapies emerged as the mainstay treatment of COVID-19 (Drozdal et al., 2021; Niknam et al., 2022). Although the development of potential drug candidates has shed some light for clinicians in treating patients with severe COVID-19 clinical symptoms, the effects of certain treatments including antiviral agents and neutralising antibody remain controversial. Some studies showed that combinational therapies generally show more promising results compared to single treatment (Zhai et al., 2023). Therefore, mass COVID-19 vaccination remains crucial in ending the pandemic status of this life-threatening virus. In Malaysia, there are a total of 7 COVID-19 vaccines that have received conditional approval by the Drug Control Authority (DCA), with more vaccines that are expected to arrive subject to the approval of DCA and the National Pharmaceutical Regulatory Agency (NPRA) (Malaysia MoH, 2021). Presently, there are three COVID-19 vaccines that are actively being administered in Malaysia: Pfizer-BioNTech (Comirnaty®), Sinovac (CoronaVac®) and Oxford-AstraZeneca (ChAdOx1-S®[recombinant]).

Since the approval and implementation of these vaccines globally, it has resulted in a reduction of at least 94% of COVID-19 infections in the vaccinated

group (Al-Kassmy et al., 2020). With the continuing upsurge in COVID-19 cases, there is rapid progress in the COVID-19 vaccination drive in Malaysia. As such, the daunting challenge faced by the Ministry of Health, Malaysia, gradually shifted from vaccination procurement and distribution to ensuring the broadest possible acceptance among all populations in this country. The term 'vaccine hesitancy' is used when one delays accepting or refusing vaccines despite the availability of vaccine services (Riad et al., 2021a). Based on available statistics dated until 31 October 2021, an overall 74.8% of the Malaysian population has been fully vaccinated, and at least 78.1% of the population has received their 1st dose (Malaysia MoF, 2021; Tang, 2021). However, despite the increasing vaccination rate in Malaysia, pockets of people are either misled by online disinformation that fuels preferences towards a specific vaccine or are unsure about vaccination, especially among people with higher education (Zainul, 2021). Several studies have reported that concerns regarding the adverse effects profile of a COVID-19 vaccine is one of the reasons behind the public's vaccine hesitancy (Dror et al., 2020; Mohamed et al., 2023; Razai et al., 2021; Saied et al., 2021). A study in the United Kingdom also revealed that the most frequent cause of vaccine hesitancy is the fear of vaccine side effects (Luyten et al., 2019).

Information that originates from half-truths, unfounded speculations and targeted disinformation rooted in conspiracy theories can mislead the public's understanding towards COVID-19 vaccines, especially their safety and efficacy profile. It has been found that information can shape an individual's perceptions and decision-making even if it is misinformation, which could eventually lead to a self-perpetuating cycle of negative news when it is left unchallenged (Faasse et al., 2012). People who were exposed to misleading or negative remarks about medication in the media reported more adverse events, thereby raising and validating other people's concerns. Therefore, strategies are necessary in addressing common misconceptions about vaccine adverse effects without elevating them through public discourse. One of the methods of tackling and decreasing COVID-19 vaccination hesitancy is to raise public awareness regarding the effectiveness of these vaccines and their side effects (Jarrett et al., 2015). Thus far, existing data on the side effects of COVID-19 vaccines revealed by manufacturer-funded studies have been included in the Clinical Guidelines on COVID-19 Vaccination in Malaysia (Malaysia MoH, 2021). In addition, various efforts have also been made by the Ministry of Health, Malaysia in identifying and addressing the side effects of COVID-19 vaccines, including clinical trials by the Institute of Clinical Research (ICR) in Malaysia which investigates the safety profile and efficacy of COVID-19 vaccines (National Institute of Health Malaysia, n.d.). The MySejahtera mobile application is another example that allows the public to report adverse effects following immunisation (AEFI) through a self-reporting method. However, it is anticipated that only moderate to severe side effects

that have an impact on the quality of life of recipients are reported, such as the reported cases received for adverse drug reactions (Banovac et al., 2017).

A few reliable methods are available to collect information on adverse drug effects. Among them are collecting practice data, spontaneous reporting through national pharmacovigilance databases, soliciting events from healthcare professionals, as well as direct observation and surveying of patients for drug-related adverse events (Mayer et al., 2010; Morimoto et al., 2004). In addition, the patient's role in reporting adverse drug effects has also long been established in a few countries (Van Grootheest & de Jong-van den Berg, 2004). Nonetheless, studies about the epidemiology of adverse drug effects in public settings are limited, especially when hospitalisation or medical intervention is not needed, which is likely for COVID-19 vaccines as well (Bouvy et al., 2015). On top of that, there is a lack of independent studies that investigate the occurrence of side effects upon receiving these COVID-19 vaccines, especially the three vaccines that are actively being distributed in Malaysia. Henceforth, the present study aims to explore the side effects profile of COVID-19 vaccines upon receiving them with the hope of educating the public on the safety profiles of these vaccines and decreasing vaccine hesitancy among the public. This study strived to explore the type of COVID-19 vaccines and the types of self-reported adverse effects following COVID-19 immunisation among the public in Malaysia.

2. Methods

2.1. Research design

A cross-sectional observational study was conducted between December 2021 and January 2022 via an online survey among citizens of Malaysia. Ethical approval was obtained from Medical and Research Ethics Committee (MREC) of Universiti Teknologi MARA (UiTM) (Code: REC/12/2021 (MR/925)). The questionnaire was constructed in such a way that self-reported symptoms experienced following COVID-19 vaccination among the public could be identified without collecting any personal identification details. Participants were required to agree to consent online to answer the survey.

2.2. Study participants

Participants who were adult Malaysians (\geq age 18 years) and (i) had received the COVID-19 vaccine at any stage of vaccination, be it dose 1 and/or dose 2 and/or dose 3, or (ii) were at least 2 weeks post-COVID-19 vaccination at any stage of vaccination, be it dose 1 and/or dose 2 and/or dose 3, were selected to participate in the study. The survey questionnaire was circulated through an internet-based survey platform (Survey Monkey), and participants were approached through social media platforms. The convenience sampling

method was applied due to the finite study period and movement control order (MCO) situation in Malaysia. As a result, a total of 901 samples were conveniently selected and used for further analysis.

2.3. Survey tool

The questionnaire was developed according to previously published articles and Clinical Guidelines on COVID-19 Vaccination in Malaysia (Kadali et al., 2021; Riad et al., 2021a). It consists of questions on demographic data, medical history, vaccination history, side effects experienced and perceptions of COVID-19 vaccines that were prepared in both English and Malay languages. In addition, a team of experts consisting of academicians and practitioners and the public conducted the face validity of the questionnaire by evaluating the presentation of the questionnaire in terms of readability, clarity of the language used, feasibility as well as the consistency of style and formatting (Taherdoost, 2016).

2.4. Sample size

Our study was conducted only among Malaysians aged 18 years and above. According to statistics available in 2022, the estimated population of Malaysians aged 18 years and above in 2021 is approximately 22 million (Statista Research Department, 2022). Using Yamane's formula with a margin error of 5% and confidence interval of 95%, the minimum sample size required is 400 (Yamane, 1967). However, 10% is required to be added to the calculated sample size to compensate for missing data. Therefore, the final sample size needed for this study was 440.

2.5. Statistical analysis

The application software 'Statistical Package for the Social Sciences (SPSS)' version 25.0 was used for all statistical analyses (Statistical Package for the Social Sciences (SPSS) version 25.0, 2020). Categorical data for demographic data and vaccine side effects were represented as frequencies, percentages, means and standard deviations. Inferential analyses, such as independent t tests, chi-square tests and Fischer's exact tests, were performed to test the study's hypothesis. A P value < 0.05 was considered to indicate statistical significance of data.

3. Results

3.1. Demographic profile of Malaysian recipients of the COVID-19 vaccine

Table 1 describes the demographic data of all the participants of this study. Based on our findings, the mean age of the respondents is 37.0 (SD = 12.6).

Table 1. Demographic profile of respondents ($n = 901$).

| Demographic profile | M | (SD) | <i>n</i> | (%) |
|--|------|--------|----------|---------|
| Age | 37.0 | (12.6) | | |
| 18–30 | | | 344 | (38.2%) |
| 31–40 | | | 252 | (28.0%) |
| 41–50 | | | 167 | (18.5%) |
| 51–60 | | | 77 | (8.5%) |
| 61–70 | | | 57 | (6.3%) |
| 71–80 | | | 4 | (0.4%) |
| Gender | | | | |
| Male | | | 217 | (24.1%) |
| Female | | | 684 | (75.9%) |
| Ethnicity | | | | |
| Malay | | | 740 | (82.1%) |
| Chinese | | | 60 | (6.7%) |
| Indian | | | 67 | (7.4%) |
| Others | | | 34 | (3.8%) |
| Education level | | | | |
| Graduate/ Post graduate degree | | | 737 | (81.8%) |
| High school/ Diploma | | | 117 | (13.0%) |
| Less than high school | | | 47 | (5.2%) |
| Comorbidities | | | | |
| Yes | | | 222 | (24.6%) |
| No | | | 679 | (75.4%) |
| Employment status | | | | |
| Employed | | | 608 | (67.5%) |
| Unemployed | | | 293 | (32.5%) |
| Previous COVID-19 infection | | | | |
| Yes | | | 92 | (10.2%) |
| No | | | 809 | (89.8%) |
| Type of vaccine received | | | | |
| Pfizer-BioNTech (Comirnaty [®]) | | | 381 | (42.3%) |
| Sinovac (CoronaVac [®]) | | | 117 | (13.0%) |
| Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | | | 127 | (14.1%) |
| Others (e.g. CanSino/Johnson & Johnson/Sinopharm) | | | 3 | (0.3%) |
| Mixed vaccines | | | 273 | (30.2%) |
| Adverse effects | | | | |
| Yes | | | 814 | (90.3%) |
| No | | | 87 | (9.7%) |

There were a total of 217 (24.1%) males and 684 (75.9%) females included in this study. Of the 901 participants who completed the survey, 740 (82.1%) were of Malay ethnicity, 737 (81.8%) held a graduate or postgraduate degree and 608 (67.5%) were employed. The majority of the respondents did not have any associated comorbidities or previous COVID-19 infection history, with findings of 679 (75.4%) and 809 (89.8%), respectively. Of the responses, a total of 381 (42.3%) people received the Pfizer-BioNTech (Comirnaty[®]) vaccine, 117 (13.0%) received the Sinovac (CoronaVac[®]) vaccine, 127 (14.1%) received the Oxford-AstraZeneca (ChAdOx1-[®][recombinant]) vaccine, and 3 (0.3%) received other types of vaccines, including the CanSino, Johnson & Johnson and Sinopharm vaccines. Meanwhile, 273 (30.2%) of the respondents received mixed vaccines, and the details are listed in Table 2. Of the 901 responses collected, 895 (99.3%) respondents

Table 2. Types of vaccines taken among mixed vaccines recipients ($n = 273$).

| Types of mixed vaccines | <i>n</i> | (%) |
|--|----------|---------|
| Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) + Sinovac (CoronaVac [®]) | 5 | (1.8%) |
| Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) + Pfizer-BioNTech (Comirnaty [®]) | 70 | (25.6%) |
| Sinovac (CoronaVac [®]) + Pfizer-BioNTech (Comirnaty [®]) | 197 | (72.2%) |
| CanSino + Pfizer-BioNTech (Comirnaty [®]) | 1 | (0.4%) |

had received more than one dose of the COVID-19 vaccine, whereas only 6 (0.7%) respondents had received a single dose.

3.2. Adverse reactions reported post-COVID-19 vaccination

Based on the responses collected, a total of 814 (90.3%) participants reported at least one adverse effect following COVID-19 immunisation. The types of symptoms experienced following COVID-19 vaccination that were reported by participants are shown in Table 3. When probed on the types of adverse reactions reported by respondents, the major adverse effects reported were swelling at the injection site ($n = 752$, 83.5%), headache ($n = 638$, 70.8%), pain or soreness at the injection site ($n = 628$, 69.7%), fatigue or tiredness ($n = 544$, 60.4%), muscle weakness ($n = 529$, 58.7%) and diarrhea ($n = 451$, 50.1%). Figure 1 portrays the percentage of these reported side effects based on the types of COVID-19 vaccines. Of them, recipients of the

Table 3. Side effects reported post COVID-19 vaccination ($n = 901$).

| Side Effects | <i>n</i> | (%) |
|------------------------------------|----------|---------|
| Local side effects | | |
| Swelling at injection site | 752 | (83.5%) |
| Pain or soreness at injection site | 628 | (69.7%) |
| Redness at injection site | 376 | (41.7%) |
| Itchiness at injection site | 271 | (30.1%) |
| Swollen lymph nodes | 117 | (13.0%) |
| Systemic side effects | | |
| Headache | 638 | (70.8%) |
| Fatigue/ Tiredness | 544 | (60.4%) |
| Muscle weakness | 529 | (58.7%) |
| Diarrhea | 451 | (50.1%) |
| Nausea | 450 | (49.9%) |
| Skin rash | 440 | (48.8%) |
| Fever | 424 | (47.1%) |
| Chills and shivering | 402 | (44.6%) |
| Muscle pain | 371 | (41.2%) |
| Malaise | 348 | (38.6%) |
| Joint pain | 371 | (41.2%) |
| Constipation | 285 | (31.6%) |
| Dizziness | 203 | (22.5%) |
| Vomiting | 176 | (19.5%) |
| Insomnia | 98 | (10.9%) |
| Runny nose | 71 | (7.9%) |
| Cough | 62 | (6.9%) |
| Sore throat | 51 | (5.7%) |




Figure 1. Side effects reported post COVID-19 vaccination based on types of COVID-19 vaccine ($n = 901$).

Pfizer-BioNTech (Comirnaty ®) vaccine reported the highest number of adverse effects ($n = 355$, 43.6%), followed by mixed COVID-19 vaccine recipients ($n = 254$, 31.2%), Oxford-AstraZeneca (ChAdOx1-®[recombinant]) vaccine




Figure 2. Side effects reported post COVID-19 vaccination based on vaccination dose ($n = 901$).

recipients ($n = 113$, 13.9%) and Sinovac (CoronaVac®) vaccine recipients ($n = 90$, 11.1%). Figure 2 depicts the self-reported adverse effects following COVID-19 immunisation based on the vaccination dose received.

3.3. Adverse effects following Pfizer-BioNTech (Comirnaty®) vaccination and demographic profiles

Table 4 shows the association between the presence of side effects post-Pfizer-BioNTech (Comirnaty®) vaccination and the demographic profile. A total of 355 (93.2%) recipients of the Pfizer-BioNTech (Comirnaty®) vaccine self-reported experiencing symptoms following vaccination. The analysis of various aspects of the demographic profile of respondents related to the reactogenicity of Pfizer-BioNTech (Comirnaty®) vaccination found that people from the elder age group (>60 years), female gender, Indian ethnicity,

Table 4. The association between adverse effects post Pfizer-BioNTech (Comirnaty®) vaccination and demographic profile ($n = 381$).

| Demographic profile | Adverse effects | | χ^2 | (df) | P value |
|------------------------------------|-----------------|----------|----------|---------|--------------------------------|
| | Yes | No | | | |
| | <i>n</i> | (%) | <i>n</i> | (%) | |
| Age | | | | | |
| 18–30 | 127 | (93.4%) | 9 | (6.6%) | 0.380 ^a (379) 0.704 |
| 31–40 | 123 | (95.3%) | 6 | (4.7%) | |
| 41–50 | 63 | (88.7%) | 8 | (11.3%) | |
| 51–60 | 20 | (90.9%) | 2 | (9.1%) | |
| 61–70 | 21 | (95.5%) | 1 | (4.5%) | |
| 71–80 | 1 | (100.0%) | 0 | (0.0%) | |
| Gender | | | | | |
| Male | 83 | (90.2%) | 9 | (9.8%) | 1.670 (1) 0.196 |
| Female | 272 | (94.1%) | 17 | (5.9%) | |
| Ethnicity | | | | | |
| Malay | 295 | (93.4%) | 21 | (6.6%) | 1.381 ^a (3) 0.710 |
| Chinese | 23 | (88.5%) | 3 | (11.5%) | |
| Indian | 26 | (96.3%) | 1 | (3.7%) | |
| Others | 11 | (91.7%) | 1 | (8.3%) | |
| Education level | | | | | |
| Graduate/ Post graduate degree | 296 | (93.7%) | 20 | (6.3%) | 2.530 ^b (2) 0.282 |
| High school/ Diploma | 43 | (93.5%) | 3 | (6.5%) | |
| Less than high school | 16 | (84.2%) | 3 | (15.8%) | |
| Comorbidities | | | | | |
| Yes | 91 | (93.8%) | 6 | (6.2%) | 0.830 (1) 0.773 |
| No | 264 | (93.0%) | 20 | (7.0%) | |
| Employment status | | | | | |
| Employed | 257 | (93.8%) | 17 | (6.2%) | 0.589 (1) 0.443 |
| Unemployed | 98 | (91.6%) | 9 | (8.4%) | |
| Previous COVID-19 infection | | | | | |
| Yes | 32 | (91.4%) | 3 | (8.6%) | 0.721 ^c |
| No | 323 | (93.3%) | 23 | (6.6%) | |

^aIndependent T-test is performed.

^bPearson Chi Square test is performed.

^cFischer exact test is performed.

higher level of education and individuals with associated comorbidities reported a statistically greater number of postvaccination adverse effects than others. Independent t tests were performed for age [$t(df) = 0.380$ (379), P value = 0.704]. There was no significant mean difference in age between respondents who reported with and without adverse effects following Pfizer-BioNTech (Comirnaty[®]) vaccination. Pearson's chi-square test was performed for sex [P value = 0.196], comorbidities [P value = 0.773], and employment status [P value = 0.443]. In addition, the Pearson chi-square test was also used for ethnicity [P value = 0.710] and education level [P value = 0.282], whereas the Fischer exact test was performed for previous COVID-19 infection [P value = 0.721]. There was no significant association observed between the demographic profile and the presence of adverse effects following Pfizer-BioNTech (Comirnaty[®]) vaccination, as shown in Table 4.

Table 5. The association between adverse effects post Sinovac (CoronaVac[®]) vaccination and demographic profile ($n = 117$).

| Demographic profile | Adverse effects | | χ^2 | (df) | P value |
|------------------------------------|-----------------|--------------------|---------------------|-------|--------------------|
| | Yes <i>n</i> | No <i>n</i> (%) | | | |
| Age | | | −0.823 ^a | (115) | 0.412 |
| 18–30 | 39 (70.9%) | 16 (29.1%) | | | |
| 31–40 | 24 (80.0%) | 6 (20.0%) | | | |
| 41–50 | 18 (5.3%) | 18 (94.7%) | | | |
| 51–60 | 5 (71.4%) | 2 (28.6%) | | | |
| 61–70 | 4 (66.7%) | 2 (33.3%) | | | |
| 71–80 | 0 (0.0%) | 0 (0.0%) | | | |
| Gender | | | 0.036 | (1) | 0.850 |
| Male | 25 (78.1%) | 7 (21.9%) | | | |
| Female | 65 (76.5%) | 20 (23.5%) | | | |
| Ethnicity | | | 2.576 ^b | (3) | 0.462 |
| Malay | 66 (75.9%) | 21 (24.1%) | | | |
| Chinese | 12 (85.7%) | 2 (14.3%) | | | |
| Indian | 10 (83.3%) | 2 (16.7%) | | | |
| Others | 2 (50.0%) | 2 (50.0%) | | | |
| Education level | | | 3.698 ^b | (2) | 0.157 |
| Graduate/ Post graduate degree | 73 (80.2%) | 18 (19.8%) | | | |
| High school/Diploma | 10 (58.8%) | 7 (41.2%) | | | |
| Less than high school | 7 (77.8%) | 2 (22.2%) | | | |
| Comorbidities | | | | | 1.000 ^c |
| Yes | 12 (80.0%) | 3 (20.0%) | | | |
| No | 78 (76.5%) | 24 (23.5%) | | | |
| Employment status | | | 1.192 | (1) | 0.275 |
| Employed | 54 (80.6%) | 13 (19.4%) | | | |
| Unemployed | 36 (72.0%) | 14 (28.0%) | | | |
| Previous COVID-19 infection | | | | | 0.761 ^c |
| Yes | 15 (83.3%) | 3 (16.7%) | | | |
| No | 75 (75.8%) | 24 (24.2%) | | | |

^aIndependent T-test is performed.

^bPearson Chi Square test is performed.

^cFischer exact test is performed.

3.4. Adverse effects following Sinovac (CoronaVac®) vaccination and demographic profile

Table 5 shows the association between the presence of adverse effects post Sinovac (CoronaVac®) vaccination and the demographic profile. A total of 90 (76.9%) recipients of the Sinovac (CoronaVac®) vaccine reported side effects following vaccination with this vaccine. The analysis of various aspects of the demographic profile related to the reactogenicity of Sinovac (CoronaVac®) vaccination among the participants found that people from the 31 to 40 age group, female gender, Chinese ethnicity, higher educational level, individuals with associated health conditions and individuals with a history of COVID-19 infection showed a higher percentage of postvaccination side effects than others. Independent t tests were performed for age [$t(df) = -0.823(115)$, P value = 0.412]. There was no significant mean difference in age between respondents who reported with and without adverse effects following Sinovac (CoronaVac®) vaccination. Pearson's chi-square test was performed for gender [P value = 0.850] and employment status [P value = 0.275]. In addition, the Pearson chi-square test was also used for ethnicity [P value = 0.462] and education level [P value = 0.157], whereas the Fisher exact test was used for comorbidities [P value = 1.000] and previous COVID-19 infection [P value = 0.761]. There was no significant association observed between the demographic profile and the presence of adverse effects following Sinovac (CoronaVac®) vaccination, as shown in Table 5.

3.5. Adverse effects following Oxford-AstraZeneca (ChAdOx1-®[recombinant]) vaccination and demographic profile

Table 6 shows the association between the presence of adverse effects post Oxford-AstraZeneca (ChAdOx1-®[recombinant]) vaccination and the demographic profile. A total of 113 (89.0%) recipients of the Oxford-AstraZeneca (ChAdOx1-®[recombinant]) vaccine reported experiencing side effects after vaccination. The analysis of various aspects of the demographic profile related to the reactogenicity of Oxford-AstraZeneca (ChAdOx1-®[recombinant]) vaccination among these participants revealed that people from the younger age group (<50 years), male gender, Indian ethnicity, lower educational status, individuals without associated comorbidities and those with previous COVID-19 infection history reported a greater percentage of postvaccination symptoms than others. The median difference in age was tested using the Mann-Whitney U test with findings of [$U = 800$, P value = 0.945]. Fisher's exact test was performed for sex [P value = 0.467], comorbidities [P value = 0.317] and previous COVID-19 infection [P value = 0.609]. In addition, the Pearson chi-square test was also used for ethnicity [P value = 0.666], education level [P value = 0.522] and employment status [P value = 0.084].

Table 6. The association between adverse effects post Oxford-AstraZeneca (ChAdOx1-® [recombinant]) vaccination and demographic profile ($n = 127$).

| Demographic profile | Adverse effects | | χ^2 | (df) | Mann-Whitney U | P value |
|------------------------------------|-----------------|--------------|--------------------|------|----------------|--------------------|
| | Yes | No | | | | |
| | <i>n</i> | <i>n</i> (%) | | | | |
| Age | | | | | 800 | 0.945 ^a |
| 18–30 | 50 (86.2%) | 8 (13.8%) | | | | |
| 31–40 | 25 (96.2%) | 1 (3.8%) | | | | |
| 41–50 | 25 (100.0%) | 0 (0.0%) | | | | |
| 51–60 | 5 (71.4%) | 2 (28.6%) | | | | |
| 61–70 | 8 (72.7%) | 3 (27.3%) | | | | |
| 71–80 | 0 (0.0%) | 0 (0.0%) | | | | |
| Gender | | | | | | 0.467 ^b |
| Male | 23 (95.8%) | 1 (4.2%) | | | | |
| Female | 90 (87.4%) | 13 (12.6%) | | | | |
| Ethnicity | | | 1.570 ^c | (3) | | 0.666 |
| Malay | 99 (89.2%) | 12 (10.8%) | | | | |
| Chinese | 4 (80.0%) | 1 (20.0%) | | | | |
| Indian | 6 (100.0%) | 0 (0.0%) | | | | |
| Others | 4 (89.0%) | 1 (11.0%) | | | | |
| Education level | | | 1.301 ^c | (2) | | 0.522 |
| Graduate/ Post graduate degree | 95 (89.6%) | 11 (10.4%) | | | | |
| High school/ Diploma | 14 (82.4%) | 3 (17.6%) | | | | |
| Less than high school | 4 (100.0%) | 0 (0.0%) | | | | |
| Comorbidities | | | | | | 0.317 ^b |
| Yes | 25 (83.3%) | 5 (16.7%) | | | | |
| No | 88 (90.7%) | 9 (9.3%) | | | | |
| Employment status | | | 2.982 | (1) | | 0.084 |
| Employed | 75 (92.6%) | 6 (7.4%) | | | | |
| Unemployed | 38 (82.6%) | 8 (17.4%) | | | | |
| Previous COVID-19 infection | | | | | | 0.609 ^b |
| Yes | 11 (100.0%) | 0 (0.0%) | | | | |
| No | 102 (87.9%) | 14 (12.1%) | | | | |

^aMann-Whitney U test is performed.^bFischer exact test is performed.^cPearson Chi Square test is performed.

The aforementioned demographic factors had P values greater than 0.05, which was not significant. Thus, we fail to reject the null hypothesis, and there is no association between these variables and the presence of adverse effects following Oxford-AstraZeneca (ChAdOx1-®[recombinant]) vaccination, as shown in Table 6.

3.6. Adverse effects following mixed COVID-19 vaccination and demographic profile

Table 7 shows the association between the presence of side effects following mixed COVID-19 vaccination and the demographic profile. A total of 254 (93.0%) recipients of the mixed vaccination reported experiencing symptoms

Table 7. The association between adverse effects post mixed COVID-19 vaccination and demographic profile ($n = 273$).

| Demographic profile | Adverse effects | | χ^2 | (df) | P value |
|---|-----------------|----------|----------|----------|--------------------------------|
| | Yes | No | | | |
| | <i>n</i> | (%) | <i>n</i> | (%) | |
| Age | | | | | 0.848 ^a (271) 0.397 |
| 18–30 | 88 | (94.6%) | 5 | (5.4%) | |
| 31–40 | 63 | (95.5%) | 3 | (4.5%) | |
| 41–50 | 47 | (90.4%) | 5 | (9.6%) | |
| 51–60 | 37 | (90.2%) | 4 | (9.8%) | |
| 61–70 | 16 | (88.9%) | 2 | (11.1%) | |
| 71–80 | 3 | (100.0%) | 0 | (0.0%) | |
| Gender | | | | | 0.269 ^b |
| Male | 61 | (89.7%) | 7 | (10.3%) | |
| Female | 193 | (94.1%) | 12 | (5.9%) | |
| Ethnicity | | | | | 4.988 ^c (3) 0.173 |
| Malay | 212 | (94.6%) | 12 | (5.4%) | |
| Chinese | 12 | (85.7%) | 2 | (14.3%) | |
| Indian | 19 | (86.4%) | 3 | (13.6%) | |
| Others | 11 | (84.6%) | 2 | (15.4%) | |
| Education level | | | | | 1.382 ^c (2) 0.501 |
| Graduate/ Post graduate degree | 208 | (93.7%) | 14 | (6.3%) | |
| High school/ Diploma | 34 | (91.9%) | 3 | (8.1%) | |
| Less than high school | 12 | (85.7%) | 2 | (14.3%) | |
| Comorbidities | | | | | 0.069 (1) 0.792 |
| Yes | 73 | (92.4%) | 6 | (7.6%) | |
| No | 181 | (93.3%) | 13 | (6.7%) | |
| Employment status | | | | | 0.911 (1) 0.340 |
| Employed | 174 | (94.1%) | 11 | (5.9%) | |
| Unemployed | 80 | (90.9%) | 8 | (9.1%) | |
| Previous COVID-19 infection | | | | | 0.116 ^b |
| Yes | 24 | (85.7%) | 4 | (14.3%) | |
| No | 230 | (93.9%) | 15 | (6.1%) | |
| Types of mixed vaccination | | | | | 17.898 ^c (3) <0.001 |
| Oxford-AstraZeneca (ChAdOx1-® [recombinant]) + Sinovac (CoronaVac®) | 5 | (100.0%) | 0 | (0.0%) | |
| CanSino + Pfizer-BioNTech (Comirnaty®) | 0 | (0.0%) | 1 | (100.0%) | |
| Sinovac (CoronaVac®) + Pfizer-BioNTech (Comirnaty®) | 180 | (91.4%) | 17 | (8.6%) | |
| Oxford-AstraZeneca (ChAdOx1-® [recombinant]) + Pfizer-BioNTech (Comirnaty®) | 69 | (98.6%) | 1 | (1.4%) | |

^aIndependent T-test is performed.^bFischer Exact test is performed.^cPearson Chi Square test is performed.

after receiving vaccination. The analysis of various aspects of the demographic profile related to the reactogenicity of mixed COVID-19 vaccines among participants showed that people from the elder age group (>70 years), female gender, Malay ethnicity, higher level of education, individuals without associated health conditions and any previous COVID-19 infection history reported a higher number of postvaccination symptoms compared to others. Independent t tests were performed for age [$t(df) = -0.848(271)$],

P value = 0.397]. There was no significant mean difference in age between respondents who reported with and without adverse effects following mixed COVID-19 vaccination. Fisher's exact test was performed for sex [P value = 0.269] and previous COVID-19 infection [P value = 0.116]. In addition, the Pearson chi-square test was also used for ethnicity [P value = 0.173], education level [P value = 0.501], comorbidities [P value = 0.792], and employment status [P value = 0.340]. Among the types of mixed vaccination recipients who completed the survey, those who had received a mixture of Oxford-AstraZeneca (ChAdOx1-[®][recombinant]) + Sinovac (CoronaVac[®]) and Oxford-AstraZeneca (ChAdOx1-[®][recombinant]) + Pfizer-BioNTech (Comirnaty[®]) reported a significantly greater percentage of experiencing postvaccination symptoms when compared to others, as shown in Table 7.

3.7. Comparison of adverse effects between Pfizer-BioNTech (Comirnaty[®]), Sinovac (CoronaVac[®]), Oxford-AstraZeneca (ChAdOx1-[®][recombinant]) and mixed COVID-19 vaccine recipients

Our findings showed that a significantly greater number of cases (93.2%) were reported among recipients of the Pfizer-BioNTech (Comirnaty[®]) vaccine than among recipients of other vaccines, including mixed COVID-19 vaccination. The comparison of reported postvaccination side effects between Pfizer-BioNTech (Comirnaty[®]), Sinovac (CoronaVac[®]), Oxford-AstraZeneca (ChAdOx1-[®][recombinant]) and mixed COVID-19 vaccine recipients had P values less than 0.05, which is significant. Thus, the null hypothesis is rejected, and there is a significant association between types of COVID-19

Table 8. Association of adverse effects with types of COVID-19 vaccine based on vaccine status.

| Adverse effects | COVID-19 vaccine status | | | | χ^2 | (df) | P value |
|---|-----------------------------|-------------|-----------------------------|-----|----------|------|-----------|
| | Single vaccine ^a | | Mixed vaccines ^b | | | | |
| | n | (%) | n | (%) | | | |
| Overall adverse effects | 560 (89.2%) | 254 (93.0%) | 3.264 | (1) | 0.071 | | |
| Local adverse effects | 523 (83.3%) | 245 (89.7%) | 6.318 | (1) | 0.012 | | |
| Systemic adverse effects | 517 (82.3%) | 236 (86.4%) | 2.355 | (1) | 0.125 | | |
| Adverse effects after 1st dose | 560 (89.2%) | 254 (93.0%) | 3.264 | (1) | 0.071 | | |
| Adverse effects after 2nd dose | 529 (84.2%) | 187 (68.5%) | 28.882 | (1) | <0.001 | | |
| Adverse effects after 3rd dose | 192 (30.6%) | 180 (65.9%) | 98.151 | (1) | <0.001 | | |
| Local adverse effects after 1st dose | 517 (82.3%) | 245 (89.7%) | 8.027 | (1) | 0.005 | | |
| Local adverse effects after 2nd dose | 474 (75.5%) | 154 (56.4%) | 32.757 | (1) | <0.001 | | |
| Local adverse effects after 3rd dose | 178 (28.3%) | 146 (53.5%) | 52.205 | (1) | <0.001 | | |
| Systemic adverse effects after 1st dose | 517 (82.3%) | 236 (86.4%) | 2.355 | (1) | 0.125 | | |
| Systemic adverse effects after 2nd dose | 440 (70.1%) | 151 (55.3%) | 18.349 | (1) | <0.001 | | |
| Systemic adverse effects after 3rd dose | 159 (25.3%) | 138 (50.5%) | 54.818 | (1) | <0.001 | | |

^a n = 628.
^b n = 273.

Table 9. Association of types of adverse effects with types of COVID-19 vaccine based on vaccine status.

| Side effects | COVID-19 vaccine status | | χ^2 | (df) | P value |
|---|-----------------------------|-----------------------------|----------|---------|-------------------|
| | Single vaccine ^a | Mixed vaccines ^b | | | |
| | n | (%) | n | (%) | |
| Pain/ Soreness at injection site | | | | | 21.337 (1) <0.001 |
| Yes | 467 | (74.4%) | 161 | (59.0%) | |
| No | 161 | (25.6%) | 112 | (41.0%) | |
| Swelling at injection site | | | | | 6.581 (1) 0.010 |
| Yes | 511 | (81.4%) | 241 | (88.3%) | |
| No | 117 | (18.6%) | 32 | (11.7%) | |
| Redness at injection site | | | | | 0.556 (1) 0.456 |
| Yes | 257 | (40.9%) | 119 | (43.6%) | |
| No | 371 | (59.1%) | 154 | (56.4%) | |
| Itchiness at injection site | | | | | 2.555 (1) 0.110 |
| Yes | 199 | (31.7%) | 72 | (26.4%) | |
| No | 429 | (68.3%) | 201 | (73.6%) | |
| Fatigue/Tiredness | | | | | 1.713 (1) 0.191 |
| Yes | 388 | (61.8%) | 156 | (57.1%) | |
| No | 240 | (38.2%) | 117 | (42.9%) | |
| Headache | | | | | 0.559 (1) 0.455 |
| Yes | 440 | (70.1%) | 198 | (72.5%) | |
| No | 188 | (29.9%) | 75 | (27.5%) | |
| Nausea | | | | | 1.231 (1) 0.267 |
| Yes | 306 | (48.7%) | 144 | (52.7%) | |
| No | 322 | (51.3%) | 129 | (47.3%) | |
| Vomiting | | | | | 0.626 (1) 0.429 |
| Yes | 127 | (20.2%) | 49 | (17.9%) | |
| No | 501 | (79.8%) | 224 | (82.1%) | |
| Muscle pain | | | | | 24.222 (1) <0.001 |
| Yes | 292 | (46.5%) | 79 | (28.9%) | |
| No | 336 | (53.5%) | 194 | (71.1%) | |
| Muscle weakness | | | | | 0.299 (1) 0.584 |
| Yes | 365 | (58.1%) | 164 | (60.1%) | |
| No | 263 | (41.9%) | 109 | (39.9%) | |
| Chills and shivering | | | | | 5.312 (1) 0.021 |
| Yes | 296 | (47.1%) | 106 | (38.8%) | |
| No | 332 | (52.9%) | 167 | (61.2%) | |
| Joint pain | | | | | 7.355 (1) 0.007 |
| Yes | 277 | (44.1%) | 94 | (34.4%) | |
| No | 351 | (55.9%) | 179 | (65.6%) | |
| Fever | | | | | 0.422 (1) 0.516 |
| Yes | 300 | (47.8%) | 124 | (45.4%) | |
| No | 328 | (52.2%) | 149 | (54.6%) | |
| Skin rash | | | | | 0.285 (1) 0.593 |
| Yes | 303 | (48.2%) | 137 | (50.2%) | |
| No | 325 | (51.8%) | 136 | (49.8%) | |
| Insomnia | | | | | 3.209 (1) 0.073 |
| Yes | 76 | (12.1%) | 22 | (8.1%) | |
| No | 552 | (87.9%) | 251 | (91.9%) | |
| Swollen lymph nodes | | | | | 0.921 (1) 0.337 |
| Yes | 86 | (13.7%) | 31 | (11.4%) | |
| No | 542 | (86.3%) | 242 | (88.6%) | |
| Malaise | | | | | 10.193 (1) 0.001 |
| Yes | 264 | (42.0%) | 84 | (30.8%) | |
| No | 364 | (58.0%) | 189 | (69.2%) | |

(Continued)

Table 9. Continued.

| Side effects | COVID-19 vaccine status | | | | χ^2 | (df) | P value |
|---------------------|-----------------------------|---------|-----------------------------|---------|----------|------|---------|
| | Single vaccine ^a | | Mixed vaccines ^b | | | | |
| | n | (%) | n | (%) | | | |
| Diarrhea | | | | | 1.958 | (1) | 0.162 |
| Yes | 324 | (51.6%) | 127 | (46.5%) | | | |
| No | 304 | (48.4%) | 146 | (53.5%) | | | |
| Cough | | | | | 1.175 | (1) | 0.278 |
| Yes | 47 | (7.5%) | 15 | (5.5%) | | | |
| No | 581 | (92.5%) | 258 | (94.5%) | | | |
| Dizziness | | | | | 0.914 | (1) | 0.339 |
| Yes | 147 | (23.4%) | 56 | (20.5%) | | | |
| No | 481 | (76.6%) | 217 | (79.5%) | | | |
| Constipation | | | | | 1.073 | (1) | 0.300 |
| Yes | 192 | (30.6%) | 93 | (34.1%) | | | |
| No | 436 | (69.4%) | 180 | (65.9%) | | | |
| Sore throat | | | | | 0.592 | (1) | 0.442 |
| Yes | 38 | (6.1%) | 13 | (4.8%) | | | |
| No | 590 | (93.9%) | 260 | (95.2%) | | | |
| Runny nose | | | | | 2.180 | (1) | 0.140 |
| Yes | 44 | (7.0%) | 27 | (9.9%) | | | |
| No | 584 | (93.0%) | 246 | (90.1%) | | | |

^a*n* = 628.^b*n* = 273.

vaccination and the presence of adverse effects following these vaccinations, as shown in [Table 8](#).

3.8. COVID-19 vaccination status and adverse effects

[Tables 8](#) and [9](#) highlight the vaccination status disparities among COVID-19 vaccine recipients, with various side effects reported. A total of 814 (90.3%), 716 (79.5%) and 372 (41.3%) people experienced side effects following the first, second and third doses of vaccination, respectively. Pearson's chi-square test was performed to evaluate the relationship between adverse effects and types of COVID-19 vaccine based on vaccine status. According to the findings in [Table 8](#), when compared with recipients who received a single vaccine, mixed vaccine recipients reported a significantly higher number of adverse effects post vaccination. However, when compared based on vaccination dosage, single vaccine recipients reported a higher number of postvaccination side effects after receiving the 2nd dose of vaccine [*P* value < 0.001]. Furthermore, certain side effects reported had *P* values less than 0.05, as shown in [Table 9](#), further indicating that there is a significant association between these side effects and types of COVID-19 vaccine based on vaccine status. These side effects included pain or soreness at the injection site, swelling at the injection site, muscle pain, chills and shivering, joint pain and malaise.

3.9. Local and systemic side effects

Among all COVID-19 vaccine type recipients who responded to our survey, mixed vaccine recipients reported a higher number of local and systemic symptoms, with 245 (89.7%) and 236 (86.4%) cases, respectively. A total of 523 (83.3%) and 517 (82.3%) people also reported local and systemic symptoms, respectively, after receiving a single type of COVID-19 vaccination. The results from [Table 8](#) also showed that a higher number of local and systemic symptoms were reported following the 2nd dose vaccination among single-type COVID-19 vaccine recipients [P value < 0.001]. Other details are explained in [Table 8](#).

3.10. Age and vaccine effects

Recipients <60 years of age were found to more commonly experience side effects after receiving COVID-19 immunisation, with a significantly greater percentage of cases reported compared to those from the elderly age group (>60 years of age). The chi-square test showed that there was a significant association between the types of COVID-19 vaccination and the number of side effects among different age groups, specifically among recipients <60 years of age, with a P value less than 0.05, as tabulated in [Table 10](#).

3.11. Severity of side effects

Of the COVID-19 vaccine recipients with reported adverse effects, 503 (61.8%) people required treatment to relieve postvaccination local and systemic symptoms. However, no severe symptoms that required hospitalisation were reported among the participants. The observed proportion of adverse events that required treatment was significantly higher among Oxford-AstraZeneca (ChAdOx1-[®][recombinant]) vaccine recipients, excluding those from the 41 to 50 year age group, as shown in [Table 11](#). Recipients of the Pfizer-BioNTech (Comirnaty [®]) vaccine with reported adverse effects from the 41 to 50-year-old age group showed a significantly higher percentage of people requiring treatment for postvaccination side effects.

4. Discussion

It is widely known that the risk of getting and spreading COVID-19 can be effectively curbed through vaccination drive (Bloom et al., [2021](#); Lipsitch & Dean, [2020](#)). However, the safety, side effects and efficacy profile of COVID-19 vaccines remain a prevailing concern globally, as the reactogenicity of these vaccines has not been completely understood to date. Following vaccination, one may experience unpleasant symptoms in the process of building immunity



Table 10. Association of number of adverse effects reported with types of COVID-19 vaccine based on age group.

| Age group | Types of COVID-19 vaccine | Number of side effects reported | | | | Adverse effects | | X ² | (df) | P value |
|-------------|--|---------------------------------|---------|-----|---------|-----------------|---------|----------------|------|---------|
| | | ≤5 | | >5 | | n | (%) | | | |
| | | n | (%) | n | (%) | | | | | |
| 18–30 years | Pfizer-BioNTech (Comirnaty [®]) | 27 | (7.1%) | 100 | (26.2%) | 127 | (33.3%) | 44.742 | (8) | <0.001 |
| | Sinovac (CoronaVac [®]) | 16 | (13.7%) | 23 | (19.7%) | 39 | (33.3%) | | | |
| | Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | 4 | (3.1%) | 46 | (36.2%) | 50 | (39.4%) | | | |
| | Mixed COVID-19 vaccine | 12 | (4.4%) | 76 | (27.8%) | 88 | (32.2%) | | | |
| 31–40 years | Pfizer-BioNTech (Comirnaty [®]) | 26 | (6.8%) | 97 | (25.5%) | 123 | (32.3%) | 20.285 | (8) | 0.009 |
| | Sinovac (CoronaVac [®]) | 10 | (8.5%) | 14 | (12.0%) | 24 | (20.5%) | | | |
| | Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | 3 | (2.4%) | 22 | (17.3%) | 25 | (19.7%) | | | |
| | Mixed COVID-19 vaccine | 15 | (5.5%) | 48 | (17.6%) | 63 | (23.1%) | | | |
| 41–50 years | Pfizer-BioNTech (Comirnaty [®]) | 3 | (0.8%) | 60 | (15.7%) | 63 | (16.5%) | 24.497 | (6) | <0.001 |
| | Sinovac (CoronaVac [®]) | 5 | (4.3%) | 13 | (11.1%) | 18 | (15.4%) | | | |
| | Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | 3 | (2.4%) | 22 | (17.3%) | 25 | (19.7%) | | | |
| | Mixed COVID-19 vaccine | 18 | (6.6%) | 29 | (10.6%) | 47 | (17.2%) | | | |
| 51–60 years | Pfizer-BioNTech (Comirnaty [®]) | 2 | (0.5%) | 18 | (4.7%) | 20 | (5.2%) | 12.851 | (6) | 0.045 |
| | Sinovac (CoronaVac [®]) | 2 | (1.7%) | 3 | (2.6%) | 5 | (4.3%) | | | |
| | Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | 0 | (0.0%) | 5 | (3.9%) | 5 | (3.9%) | | | |
| | Mixed COVID-19 vaccine | 16 | (5.9%) | 21 | (7.7%) | 37 | (13.6%) | | | |
| 61–70 years | Pfizer-BioNTech (Comirnaty [®]) | 6 | (1.6%) | 15 | (3.9%) | 21 | (5.5%) | 9.454 | (6) | 0.150 |
| | Sinovac (CoronaVac [®]) | 0 | (0.0%) | 4 | (3.4%) | 4 | (3.4%) | | | |
| | Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | 4 | (3.1%) | 4 | (3.1%) | 8 | (6.3%) | | | |
| | Mixed COVID-19 vaccine | 8 | (2.9%) | 8 | (2.9%) | 16 | (5.9%) | | | |
| 71–80 years | Pfizer-BioNTech (Comirnaty [®]) | 0 | (0.0%) | 1 | (0.3%) | 1 | (0.3%) | 1.333 | (1) | 0.248 |
| | Sinovac (CoronaVac [®]) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | | | |
| | Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | | | |
| | Mixed COVID-19 vaccine | 2 | (0.7%) | 1 | (0.4%) | 3 | (1.1%) | | | |

Table 11. Association of treatment for post COVID-19 vaccination adverse effects with types of COVID-19 vaccine based on age group.

| Age group | Types of COVID-19 vaccine | Treatment for adverse effects | | | | χ^2 | (df) | P value |
|-------------|--|-------------------------------|----------|-----|---------|----------|------|--------------------|
| | | No | | Yes | | | | |
| 18–30 years | Pfizer-BioNTech (Comirnaty [®]) | 44 | (34.6%) | 83 | (65.4%) | 41.200 | (4) | <0.001 |
| | Sinovac (CoronaVac [®]) | 28 | (71.8%) | 11 | (28.2%) | | | |
| | Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | 10 | (20.0%) | 40 | (80.0%) | | | |
| 31–40 years | Mixed COVID-19 vaccine | 26 | (29.5%) | 62 | (70.5%) | 11.305 | (4) | 0.023 |
| | Pfizer-BioNTech (Comirnaty [®]) | 46 | (37.4%) | 77 | (62.6%) | | | |
| | Sinovac (CoronaVac [®]) | 14 | (58.3%) | 10 | (41.7%) | | | |
| | Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | 6 | (24.0%) | 19 | (76.0%) | | | |
| 41–50 years | Mixed COVID-19 vaccine | 26 | (41.3%) | 37 | (58.7%) | 8.876 | (3) | 0.031 |
| | Pfizer-BioNTech (Comirnaty [®]) | 14 | (22.2%) | 49 | (77.8%) | | | |
| | Sinovac (CoronaVac [®]) | 10 | (55.6%) | 8 | (44.4%) | | | |
| | Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | 9 | (36.0%) | 16 | (64.0%) | | | |
| 51–60 years | Mixed COVID-19 vaccine | 23 | (48.9%) | 24 | (51.1%) | 1.338 | (3) | 0.720 |
| | Pfizer-BioNTech (Comirnaty [®]) | 9 | (45.0%) | 11 | (55.0%) | | | |
| | Sinovac (CoronaVac [®]) | 3 | (60.0%) | 2 | (40.0%) | | | |
| | Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | 2 | (40.0%) | 3 | (60.0%) | | | |
| 61–70 years | Mixed COVID-19 vaccine | 16 | (43.2%) | 21 | (56.8%) | 1.690 | (3) | 0.639 |
| | Pfizer-BioNTech (Comirnaty [®]) | 8 | (38.1%) | 13 | (61.9%) | | | |
| | Sinovac (CoronaVac [®]) | 2 | (50.0%) | 2 | (50.0%) | | | |
| | Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | 2 | (25.0%) | 6 | (75.0%) | | | |
| 71–80 years | Mixed COVID-19 vaccine | 8 | (50.0%) | 8 | (50.0%) | | | 1.000 ^a |
| | Pfizer-BioNTech (Comirnaty [®]) | 1 | (100.0%) | 0 | (0.0%) | | | |
| | Sinovac (CoronaVac [®]) | 0 | (0.0%) | 0 | (0.0%) | | | |
| | Oxford-AstraZeneca (ChAdOx1- [®] [recombinant]) | 0 | (0.0%) | 0 | (0.0%) | | | |
| | Mixed COVID-19 vaccine | 2 | (66.7%) | 1 | (33.3%) | | | |

^aFischer Exact test is performed.

depending on various factors, including the type of vaccine received, its composition, route of administration and host characteristics, which include age, gender and others (Hervé et al., 2019). According to studies, there is a vast difference in awareness, perception and acceptance of the COVID-19 vaccine among the public (Adedeji-Adenola et al., 2022; Batarseh et al., 2021; Enitan et al., 2020). Hesitancy towards receiving COVID-19 vaccines among the public is complicated by various factors, including concerns about the development of vaccines at an unprecedented rate and the assurance of the safety and effectiveness of these vaccines (Batteux et al., 2022; Jennings et al., 2021). As such, there is a need to monitor vaccine hesitancy, and authorities should consider various initiatives to encourage more participation in vaccination drive, in particular, these programmes should aim to address the factors underpinning vaccine hesitancy. Therefore, we conducted this study to explore the probable symptoms experienced following COVID-19 vaccination so that this information can be used to educate the public on the safety profile of COVID-19

vaccine to optimise COVID-19 vaccine uptake in Malaysia. The findings from this study revealed that the predictors of COVID-19 vaccination that are significant at the 5% level of significance are age, gender, type of COVID-19 vaccine and vaccination dose. These predictors are needed due to the diversity in vaccination response and its corresponding cellular changes of immune system post vaccination (Plotkin, 2010; Pulendran, 2014). For instance, a Saudi Arabia nationwide study identified the level of education, nationality of respondents, gender and general health status as significant predictors of severe adverse reactions following COVID-19 vaccination (Almalki et al., 2022). Another study in Turkey also identified gender and age as predictors of side effects following COVID-19 vaccination (Riad et al., 2021b).

Our findings revealed that 90.3% of the study participants reported at least one symptom following COVID-19 vaccination. However, none of them reported serious effects towards any of the COVID-19 vaccines received. Based on the results of our study, recipients of these COVID-19 vaccines can primarily expect the following symptoms following vaccination: swelling at the injection site, pain or soreness at the injection site, headache, fatigue or tiredness, muscle weakness and diarrhea. The most common adverse effects experienced among single vaccine recipients (e.g. Pfizer-BioNTech (Comirnaty[®]), Sinovac (CoronaVac[®]), Oxford-AstraZeneca (ChAdOx1-[®][recombinant]) and others (e.g. CanSino/Johnson & Johnson/Sinopharm)) were pain or soreness at the injection site, swelling at the injection site, fatigue or tiredness, headache, nausea, muscle pain, muscle weakness, chills and shivering, fever, skin rash, malaise and diarrhea. Meanwhile, symptoms such as pain or soreness at the injection site, swelling at the injection site, fatigue or tiredness, headache, nausea, muscle weakness and skin rash were found to be the most common side effects reported by mixed COVID-19 vaccine recipients. The least reported adverse effects among single vaccine recipients (e.g. Pfizer-BioNTech (Comirnaty[®]), Sinovac (CoronaVac[®]) and Oxford-AstraZeneca (ChAdOx1-[®][recombinant])) were cough, sore throat and runny nose, while among mixed vaccine recipients, symptoms such as insomnia, cough, sore throat and runny nose were the least reported symptoms. Interestingly, although swollen lymph nodes have been reported as the rarest adverse effect among vaccine recipients such as Pfizer-BioNTech (Comirnaty[®]) in a recent study, our findings showed otherwise (El-Shitany et al., 2021). Approximately 64, 13, 13 and 31 study participants reported experiencing swollen lymph nodes following vaccination with the Pfizer-BioNTech (Comirnaty[®]) vaccine, Sinovac (CoronaVac[®]) vaccine, Oxford-AstraZeneca (ChAdOx1-[®][recombinant]) vaccine and mixed vaccine, respectively. Among these mixed vaccine recipients, 12 were recipients of Oxford-AstraZeneca (ChAdOx1-[®][recombinant]) + Pfizer-BioNTech (Comirnaty[®]) vaccines, 1 was a recipient of Oxford-AstraZeneca (ChAdOx1-[®][recombinant]) + Sinovac (CoronaVac[®]) vaccines and 18

were recipients of Sinovac (CoronaVac®) + Pfizer-BioNTech (Comirnaty ®) vaccines. Furthermore, the reported adverse effects were similar to those described in the safety and efficacy studies of COVID-19 vaccines, including those that were concluded in the Clinical Guidelines on COVID-19 Vaccination in Malaysia but with a higher percentage of cases observed in this study (Malaysia MoH, 2021; Menni et al., 2021; Nassar et al., 2022; Saeed et al., 2021; Zhang et al., 2021).

Based on this study, side effects were significantly greater among the elderly age group among Pfizer-BioNTech (Comirnaty ®) vaccine and mixed vaccine recipients, which is similar to the findings from other studies (Nassar et al., 2022; Omeish et al., 2022). In contrast, recipients of the Sinovac (CoronaVac®) vaccine and Oxford-AstraZeneca (ChAdOx1-®[recombinant]) vaccine showed otherwise. A study by Saeed *et al.* reported similar results among Sinopharm vaccine recipients (Saeed et al., 2021). Several other studies have shown that individuals from younger age groups are more likely to experience postvaccination side effects than individuals from older age groups (Doroftei et al., 2021). In addition, our study also found that female recipients of Pfizer-BioNTech (Comirnaty®), Sinovac (CoronaVac®) and mixed vaccination reported significantly higher statistics of adverse effects, which is similar to the trend reported in other studies (Camacho Moll et al., 2022; Cuschieri et al., 2021; Mohammed et al., 2021). Various factors could contribute to the cause of the gender disparity in vaccine side effects. The differences in male and female hormones are highly associated with variations in immune responses in individuals. Several studies have reported that testosterone plays a role in the suppressive action of the immune response in adult males, whereas estradiol is related to a higher immune response against viral infections in adult females (Di Resta et al., 2021; Potluri et al., 2019). This theory could be a plausible explanation for why female participants reported more postvaccination adverse effects than male participants in this study. Nonetheless, this could also be attributed to the higher percentage (75.9%) of female participants in this study. Furthermore, participants of Indian ethnicity reported a significantly greater number of cases experiencing symptoms following vaccination with the Pfizer-BioNTech (Comirnaty ®) vaccine and Oxford-AstraZeneca (ChAdOx1-®[recombinant]) vaccine. Meanwhile, recipients of Chinese ethnicity and Malay ethnicity were found to have higher side effects reported following vaccination with Sinovac (CoronaVac®) vaccine and mixed COVID-19 vaccines, respectively. A significantly greater percentage of people experiencing side effects was reported among COVID-19 vaccine recipients of higher educational status, excluding recipients of the Oxford-AstraZeneca (ChAdOx1-®[recombinant]) vaccine, which showed an opposing result. According to existing studies, the level of education and employment status are among the factors that positively impact vaccine acceptance (Gagneux-Brunon et al.,

2021; Maraqa et al., 2021). For instance, a linear relationship was observed between level of education and acceptance of vaccine in a study (Shekhar et al., 2021). Similarly, the results from our study also showed that the majority of the participants were at a higher educational level and had a job. In addition, individuals with associated comorbidities were found to have a significant association with adverse effects following vaccination with the Pfizer-BioNTech (Comirnaty[®]) vaccine as well as the Sinovac (CoronaVac[®]) vaccine. This finding is in line with another study that demonstrated that the magnitude of COVID-19 side effects was comparatively higher among individuals associated with comorbidities (Alemayehu et al., 2022). In addition, this result is also aligned with the findings of studies that demonstrated a significant association of comorbidities with the development, frequency and severity of postvaccination side effects (Alghamdi et al., 2021; Ganesan et al., 2022; Hatmal et al., 2022). In contrast, another study conducted in Turkey reported no association between chronic illness and post-Sinovac (CoronaVac[®]) vaccination side effects (Riad et al. 2021b). Differences in the study population and type of COVID-19 vaccines could be the reason behind the inconsistency of results. Moreover, evidence from a recent study also portrayed a lower frequency of side effects following Sinovac (CoronaVac[®]) vaccination compared to other COVID-19 vaccines (Elnaem et al., 2021). These findings suggest the relationship between types of COVID-19 vaccine and the frequency of postvaccination side effects. We also discovered that individuals with a history of previous COVID-19 infection showed more side effects following vaccination with the Sinovac (CoronaVac[®]) vaccine and Oxford-AstraZeneca (ChAdOx1-[®][recombinant]) vaccine, which is similar to the findings of other studies (Krammer et al., 2021; Saadat et al., 2021; Wise, 2021).

Before the introduction of mixed COVID-19 vaccination, it was a common practice to mix vaccines and use vaccines of different platforms as a subsequent second dose of vaccination or as a booster dose to improve the results of immunisation. A variety of techniques have been utilised, including different vaccine formulations between vaccine doses, in which encouraging results have been obtained. To date, studies have shown that higher immunity is achieved in both animal models and human trials when DNA and vector vaccines have been mixed together (Lin et al., 2010; Saeedi et al., 2014; Wang et al., 2008). In addition, scientific evidence has shown that mixtures of DNA vaccines with protein vaccines or viral and protein vaccines as well as virus-like particle vaccines with DNA vaccines have all been proven to produce greater immune responses among recipients (Alekseeva et al., 2009; Lu, 2009). Our study demonstrated similar results that support this finding in which, compared to single COVID-19 vaccine recipients, individuals who received mixed COVID-19 vaccination reported a statistically greater percentage of postvaccination symptoms. A few recent studies showed similar

results, which could possibly suggest that mixed vaccination may increase vaccine reactogenicity, especially systemic reactogenicity (Alshahrani & Alqahtani, 2022; Borobia et al., 2021; Hillus et al., 2021; Vogel, 2021). It is not clear why participants who received a single type of COVID-19 vaccination reported a statistically greater number of cases experiencing symptoms after receiving the 2nd dose of vaccination in contrast to mixed vaccination. Among the single vaccine recipients who had reported postvaccination side effects, Pfizer-BioNTech (Comirnaty[®]) vaccine recipients reported a significantly greater percentage of postvaccination symptoms compared to other single COVID-19 vaccines. In a study comparing Pfizer-BioNTech (Comirnaty[®]) and Sinopharm vaccines, more moderate to severe side effects were reported following Pfizer-BioNTech (Comirnaty[®]) vaccination (Hatmal et al., 2021). Another study concluded that local side effects were more common following Pfizer-BioNTech (Comirnaty[®]) vaccination (Menni et al., 2021). Although no severe adverse events that required hospitalisation were reported, 503 (61.8%) participants still required treatment to relieve postvaccination local and systemic symptoms. The observed proportion of adverse effects that required treatment was significantly higher among Oxford-AstraZeneca (ChAdOx1-[®][recombinant]) vaccine recipients, excluding those from the 41 to 50 year age group, as shown in Table 11. Our study provides evidence of mild symptoms, as participants in our study did not consult a physician for their adverse effects following immunisation. These side effects were managed conservatively, followed by self-mediations such as paracetamols, aspirin, antihistamines and medications of chronic illness such as antihypertensive medications. This is consistent with a recent study that reported that 64% of health care workers in Ethiopia used paracetamol as a remedy for the side effects they experienced.

5. Strengths and limitations

At the time of writing this article, this is the first study in Malaysia to assess the types of self-reported post-COVID-19 vaccination side effects associated with different COVID-19 vaccine regimens, to the best of our knowledge. However, this study has a few limitations. First, due to the pandemic and Movement Control Order (MCO) in Malaysia, this study was conducted via an online survey in which data collection was performed as a self-report survey and its dissemination depended on the authors' networks. This might result in a reporting bias and recall bias that cannot be disregarded in this study. Furthermore, our sampling method may limit the possibility of generalising our results to a larger population. Aside from that, the sample size of the two groups (single and mixed vaccination) was not comparable. A total of 628 participants were from the single vaccine group, whereas only 273 participants were in the mixed vaccine group. This is highly likely due to the implementation of the

COVID-19 vaccination regimen during the shortage of vaccines in Malaysia. This study also focused on the short-term postvaccination side effects, as the latent effects following COVID-19 vaccination were not studied or included in this study. Given these limitations, a clinical trial model evaluating the adverse effects between single and mixed COVID-19 vaccination is therefore recommended to (1) confirm and explore the types of postvaccination adverse effects based on types of COVID-19 vaccination, (2) provide information for educational purposes so that the public's concerns towards the COVID-19 vaccine can be better addressed and (3) increase the COVID-19 vaccine acceptance rate and reduce vaccine hesitancy among the public.

6. Conclusion

This study demonstrated the types of self-reported adverse effects following immunisation with single and mixed COVID-19 vaccines in Malaysia. Being older, female gender, mixed COVID-19 vaccination and number of vaccine dose were among the significant predictors of COVID-19 vaccine related side effects among COVID-19 vaccinated people in Malaysia. We also found that participants who received mixed COVID-19 vaccination reported significantly more local and systemic symptoms after the first and third doses compared with single-type COVID-19 vaccine recipients. By revealing the differences of the side effects for each single and mixed vaccines implemented in Malaysia, this study may thus provide better understanding for the public, and provide important baseline for regulatory agencies worldwide to carefully consider the risk-benefit profile of vaccine to make informed decisions during public health emergencies in future. Our findings on the side effects of these COVID-19 vaccines would also be highly beneficial for health authorities, pharmaceutical companies and government in shaping health policies and outreach programmes to facilitate immunisation programme in Malaysia against future health crisis. The findings from the present study could influence regulatory decision making and adjustments in pharmaceutical policies and regulations. Regulatory bodies may update guidelines, refine approval processes or implement new measures to enhance vaccine safety and efficacy. The results of the present study could also be further explored in the context of vaccine pre-medications to lessen the severity of side effects following vaccination. In summary, this present study has had far-reaching implications for the pharmacy community, health authorities and pharmaceutical policy and regulations globally. It underscores the importance of ongoing surveillance, collaboration and transparent communication to ensure the continued success of vaccination efforts and public health initiatives. Considering the possibility of different types of COVID-19 vaccination received among respondents, similar studies should be carried out in the future as a follow-up to explore the reactogenicity of these vaccines

and the factors associated with greater odds of postvaccination symptoms to overcome vaccine hesitancy among the public.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Notes on contributors

Mahmathi Karuppannan is an Associate Professor at Faculty of Pharmacy, UiTM with a research interest in medication and patient safety, pharmacoepidemiology, pharmacy education, health economics and digital health.

Long Chiau Ming is a professor and Associate Dean (Research and Postgraduate Studies) at the School of Medical and Life Sciences, Sunway University, Malaysia.

Mohd Shahezwan Abd Wahab is a senior lecturer at Faculty of Pharmacy, UiTM with a research interest in geriatric population, traditional and alternative medicine and pharmacy education.

Zakiah Mohd Noordin is a dedicated lecturer at the Faculty of Pharmacy, Universiti Teknologi MARA. With a Master's in Clinical Pharmacy and a Bachelor's in Pharmacy, her research interests include Smoking Cessation, Dementia Care and Pharmacy Education, showcasing her commitment to advancing pharmaceutical knowledge and patient care.

Shermaine Yee is a medical graduate from the Faculty of Medicine at Quest International University.

Andi Hermansyah is the Head of Department at the Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Indonesia.

ORCID

Mahmathi Karuppannan  <http://orcid.org/0000-0002-6503-3191>

Long Chiau Ming  <http://orcid.org/0000-0002-6971-1383>

Mohd Shahezwan Abd Wahab  <http://orcid.org/0000-0002-2801-0134>

Zakiah Mohd Noordin  <http://orcid.org/0000-0002-1198-7184>

Shermaine Yee  <http://orcid.org/0000-0002-7670-0295>

Andi Hermansyah  <http://orcid.org/0000-0002-9716-3126>

References

- Adedeji-Adenola, H., Olugbake, O. A., & Adeosun, S. A. (2022). Factors influencing COVID-19 vaccine uptake among adults in Nigeria. *PLoS One*, 17(2), e0264371. <https://doi.org/10.1371/journal.pone.0264371>
- Alekseeva, E., Sominskaya, I., Skrastina, D., Egorova, I., Starodubova, E., Kushners, E., Mihailova, M., Petrakova, N., Bruvere, R., Kozlovskaya, T., Isaguliants, M., & Pumpens, P. (2009). Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: Advantages of the heterologous DNA prime, protein boost immunization regimen. *Genetic Vaccines and Therapy*, 7(1), 1–17. <https://doi.org/10.1186/1479-0556-7-7>

- Alemayehu, A., Demissie, A., Yusuf, M., Abdullahi, Y., Abdulwehab, R., Oljira, L., & Feleke, D. (2022). COVID-19 vaccine side effect: Age and gender disparity in adverse effects following the first dose of AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia: A community-based study. *SAGE Open Medicine*, 10, 20503121221108616.
- Alghamdi, A. N., Alotaibi, M. I., Alqahtani, A. S., Al Aboud, D., & Abdel-Moneim, A. S. (2021). BNT162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees. *Frontiers in Medicine*, 8, 760047. <https://doi.org/10.3389/fmed.2021.760047>
- Al-Kassmy, J., Pedersen, J., & Kobinger, G. (2020). Vaccine candidates against coronavirus infections. Where does COVID-19 stand? *Viruses*, 12(8), 861. <https://doi.org/10.3390/v12080861>
- Almalki, O. S., Khalifa, A. S., Alhemeidi, O. F., Ewis, A. A., Shady, A. M., & Abdelwahab, S. F. (2022). Correlation between the severity of COVID-19 vaccine-related adverse events and the blood group of the vaccinees in Saudi arabia: A web-based survey. *Frontiers in Pharmacology*, 13, 1006333. <https://doi.org/10.3389/fphar.2022.1006333>
- Alshahrani, M., & Alqahtani, A. (2022). Side effects of mixing vaccines against COVID-19 infection among Saudi population. *Vaccines*, 10(4), 519. <https://doi.org/10.3390/vaccines10040519>
- Banovac, M., Candore, G., Slattery, J., Houyez, F., Haerry, D., Genov, G., & Arlett, P. (2017). Patient reporting in the EU: Analysis of EudraVigilance data. *Drug Safety*, 40(7), 629–645. <https://doi.org/10.1007/s40264-017-0534-1>
- Batarseh, Y. S., Darwish ElHajji, F. W., Shammass, S., Darwish, R. M., Fakhoury, R., Al Haj Ahmad, M., Al Rusasi, A., & Jarrar, L. (2021). Perception and attitude of the public on vaccine practices and pharmacists as immunizers in Jordan. *Journal of Pharmaceutical Health Services Research*, 12(2), 114–121. <https://doi.org/10.1093/jphsr/rmaa009>
- Batteux, E., Mills, F., Jones, L. F., Symons, C., & Weston, D. (2022). The effectiveness of interventions for increasing COVID-19 vaccine uptake: A systematic review. *Vaccines*, 10(3), 386. <https://doi.org/10.3390/vaccines10030386>
- Bloom, D. E., Cadarette, D., & Ferranna, M. (2021). The societal value of vaccination in the age of COVID-19. *American Journal of Public Health*, 111(6), 1049–1054. <https://doi.org/10.2105/AJPH.2020.306114>
- Borobia, A. M., Carcas, A. J., Pérez-Olmeda, M., Castaño, L., Bertran, M. J., García-Pérez, J., Campins, M., Portolés, A., González-Pérez, M., García Morales, M. T., Arana-Arri, E., Aldea, M., Díez-Fuertes, F., Fuentes, I., Ascaso, A., Lora, D., Imaz-Ayo, N., Barón-Mira, L. E., Agustí, A., ... Torvisco, J. M. (2021). Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. *The Lancet*, 398(10295), 121–130. [https://doi.org/10.1016/S0140-6736\(21\)01420-3](https://doi.org/10.1016/S0140-6736(21)01420-3)
- Bouvy, J. C., De Bruin, M. L., & Koopmanschap, M. A. (2015). Epidemiology of adverse drug reactions in Europe: A review of recent observational studies. *Drug Safety*, 38(5), 437–453. <https://doi.org/10.1007/s40264-015-0281-0>
- Camacho Moll, M. E., Salinas Martínez, A. M., Tovar Cisneros, B., García Onofre, J. I., Navarrete Floriano, G., & Bermúdez de León, M. (2022). Extension and severity of self-reported side effects of seven COVID-19 vaccines in Mexican population. *Frontiers in Public Health*, 10, 834744. <https://doi.org/10.3389/fpubh.2022.834744>
- Cuschieri, S., Borg, M., Agius, S., Souness, J., Brincat, A., & Grech, V. (2021). Adverse reactions to Pfizer-BioNTech vaccination of healthcare workers at Malta's state hospital.

- International Journal of Clinical Practice*, 75(10), e14605. <https://doi.org/10.1111/ijcp.14605>
- Di Resta, C., Ferrari, D., Viganò, M., Moro, M., Sabetta, E., Minerva, M., Ambrosio, A., Locatelli, M., & Tomaiuolo, R. (2021). The gender impact assessment among health-care workers in the SARS-CoV-2 vaccination—an analysis of serological response and side effects. *Vaccines*, 9(5), 522. <https://doi.org/10.3390/vaccines9050522>
- Doroftei, B., Ciobica, A., Ilie, O.-D., Maftai, R., & Ilea, C. (2021). Mini-review discussing the reliability and efficiency of COVID-19 vaccines. *Diagnostics*, 11(4), 579. <https://doi.org/10.3390/diagnostics11040579>
- Dror, A. A., Eisenbach, N., Taiber, S., Morozov, N. G., Mizrahi, M., Zigran, A., Srouji, S., & Sela, E. (2020). Vaccine hesitancy: The next challenge in the fight against COVID-19. *European Journal of Epidemiology*, 35(8), 775–779. <https://doi.org/10.1007/s10654-020-00671-y>
- Drozdal, S., Rosik, J., Lechowicz, K., Machaj, F., Szostak, B., Przybyciński, J., Lorzadeh, S., Kotfis, K., Ghavami, S., & Łos, M. J. (2021). An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. *Drug Resistance Updates*, 59, 100794. <https://doi.org/10.1016/j.drug.2021.100794>
- Elnaem, M. H., Mohd Taufek, N. H., Ab Rahman, N. S., Mohd Nazar, N. I., Zin, C. S., Nuffer, W., & Turner, C. J. (2021). COVID-19 vaccination attitudes, perceptions, and side effect experiences in Malaysia: Do age, gender, and vaccine type matter? *Vaccines*, 9(10), 1156. <https://doi.org/10.3390/vaccines9101156>
- El-Shitany, N. A., Harakeh, S., Badr-Eldin, S. M., Bagher, A. M., Eid, B. G., Almukadi, H. S., Alghamdi, B. S., Alahmadi, A. A., Hassan, N. A., Sindi, N., Alghamdi, S. A., Almohaimeed, H. M., Mohammedsleh, Z. M., Al-Shaikh, T. M., Almuhayawi, M. S., Ali, S. S., & El-Hamamsy, M. (2021). Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. *International Journal of General Medicine*, 14, 1389–1401. <https://doi.org/10.2147/IJGM.S310497>
- Enitan, S. S., Oyekale, A., Akele, R., Olawuyi, K. A., Olabisi, E. O., Nwankit, A. J., Adejumo, E. N., & Enitan, C. B. (2020). Assessment of knowledge, perception and readiness of Nigerians to participate in the COVID-19 vaccine trial. *International Journal of Vaccines and Immunization*, 4(1), 1–13.
- Faasse, K., Gamble, G., Cundy, T., & Petrie, K. J. (2012). Impact of television coverage on the number and type of symptoms reported during a health scare: A retrospective pre–post observational study. *Bmj Open*, 2(4), e001607. <https://doi.org/10.1136/bmjopen-2012-001607>
- Gagneux-Brunon, A., Detoc, M., Bruel, S., Tardy, B., Rozaire, O., Frappe, P., & Botelho-Nevers, E. (2021). Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: A cross-sectional survey. *Journal of Hospital Infection*, 108, 168–173. <https://doi.org/10.1016/j.jhin.2020.11.020>
- Ganesan, S., Al Ketbi, L. M. B., Al Kaabi, N., Al Mansoori, M., Al Maskari, N. N., Al Shamsi, M. S., Alderei, A. S., El Eissae, H. N., Al Ketbi, R. M., Al Shamsi, N. S., Saleh, K. M., Al Blooshi, A. F., Cantarutti, F. M., Warren, K., Ahamed, F., & Zaher, W. (2022). Vaccine side effects following COVID-19 vaccination among the residents of the UAE—an observational study. *Frontiers in Public Health*, 10, 876336. <https://doi.org/10.3389/fpubh.2022.876336>
- Hatmal, M., Al-Hatamleh, M. A., Olaimat, A. N., Hatmal, M., Alhaj-Qasem, D. M., Olaimat, T. M., & Mohamud, R. (2021). Side effects and perceptions following COVID-19 vaccination in Jordan: A randomized, cross-sectional study implementing machine

- learning for predicting severity of side effects. *Vaccines*, 9(6), 556. <https://doi.org/10.3390/vaccines9060556>
- Hatmal, M., Al-Hatamleh, M. A., Olaimat, A. N., Mohamud, R., Fawaz, M., Kateeb, E. T., Alkhairy, O. K., Tayyem, R., Lounis, M., Al-Raei, M., Dana, R. K., Al-Ameer, H. J., Taha, M. O., & Bindayna, K. M. (2022). Reported adverse effects and attitudes among Arab populations following COVID-19 vaccination: A large-scale multinational study implementing machine learning tools in predicting post-vaccination adverse effects based on predisposing factors. *Vaccines*, 10(3), 366. <https://doi.org/10.3390/vaccines10030366>
- Hervé, C., Laupèze, B., Del Giudice, G., Didierlaurent, A. M., & Tavares Da Silva, F. (2019). The how's and what's of vaccine reactogenicity. *npj Vaccines*, 4(1), 39. <https://doi.org/10.1038/s41541-019-0132-6>
- Hillus, D., Schwarz, T., Tober-Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch, S., Helbig, E. T., Lippert, L. J., Tscheak, P., Schmidt, M. L., Riege, J., Solarek, A., von Kalle, C., Dang-Heine, C., Gruell, H., Kopankiewicz, P., Suttorp, N., Drosten, C., ... Zvorc, S. (2021). Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: A prospective cohort study. *The Lancet Respiratory Medicine*, 9(11), 1255–1265. [https://doi.org/10.1016/S2213-2600\(21\)00357-X](https://doi.org/10.1016/S2213-2600(21)00357-X)
- Jarrett, C., Wilson, R., O'Leary, M., Eckersberger, E., & Larson, H. J. (2015). Strategies for addressing vaccine hesitancy—A systematic review. *Vaccine*, 33(34), 4180–4190. <https://doi.org/10.1016/j.vaccine.2015.04.040>
- Jennings, W., Stoker, G., Bunting, H., Valgarðsson, V. O., Gaskell, J., Devine, D., McKay, L., & Mills, M. C. (2021). Lack of trust, conspiracy beliefs, and social media use predict COVID-19 vaccine hesitancy. *Vaccines*, 9(6), 593. <https://doi.org/10.3390/vaccines9060593>
- Kadali, R. A., Janagama, R., Peruru, S., & Malayala, S. V. (2021). Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. *International Journal of Infectious Diseases*, 106, 376–381. <https://doi.org/10.1016/j.ijid.2021.04.047>
- Krammer, F., Srivastava, K., team, P., & Simon, V. (2021). Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. *MedRxiv*. 2021.01.29.21250653.
- Lin, K., Roosinovich, E., Ma, B., Hung, C.-F., & Wu, T.-C. (2010). Therapeutic hpv DNA vaccines. *Immunologic Research*, 47(1-3), 86–112. <https://doi.org/10.1007/s12026-009-8141-6>
- Lipsitch, M., & Dean, N. E. (2020). Understanding COVID-19 vaccine efficacy. *Science*, 370(6518), 763–765. <https://doi.org/10.1126/science.abe5938>
- Lu, S. (2009). Heterologous prime–boost vaccination. *Current Opinion in Immunology*, 21(3), 346–351. <https://doi.org/10.1016/j.coi.2009.05.016>
- Luyten, J., Bruyneel, L., & Van Hoek, A. J. (2019). Assessing vaccine hesitancy in the UK population using a generalized vaccine hesitancy survey instrument. *Vaccine*, 37(18), 2494–2501. <https://doi.org/10.1016/j.vaccine.2019.03.041>
- Malaysia MoF. (2021). *Malaysia's 2Q 2021 GDP grows by 16.1%; Economy expected to continue on recovery path*. [https://www.mof.gov.my/portal/en/news/press-release/malaysia-s-2q-2021-gdp-grows-by-16-1-economy-expected-to-continue-on-recovery-path#:~:text=Press%20Release,Malaysia's%202Q%202021%20GDP%20Grows%20by%2016.1%25%3B,to%20Continue%20on%20Recovery%20Path&text=Bank%20Negara%20Malaysia%20\(BNM\)%20and,of%202021%20\(Q%202021\)](https://www.mof.gov.my/portal/en/news/press-release/malaysia-s-2q-2021-gdp-grows-by-16-1-economy-expected-to-continue-on-recovery-path#:~:text=Press%20Release,Malaysia's%202Q%202021%20GDP%20Grows%20by%2016.1%25%3B,to%20Continue%20on%20Recovery%20Path&text=Bank%20Negara%20Malaysia%20(BNM)%20and,of%202021%20(Q%202021))
- Malaysia MoH. (2021). *Clinical guidelines on COVID-19 vaccination in Malaysia* (4th ed.).

- Maraqa, B., Nazzal, Z., Rabi, R., Sarhan, N., Al-Shakhra, K., & Al-Kaila, M. (2021). COVID-19 vaccine hesitancy among health care workers in Palestine: A call for action. *Preventive Medicine*, 149, 106618. <https://doi.org/10.1016/j.ypmed.2021.106618>
- Mayer, M. H., Dowsett, S. A., Brahmavar, K., Hornbuckle, K., & Brookfield, W. (2010). Reporting adverse drug events. *U. S. Pharmacist*, 35(4), HS-15–HS-19.
- Menni, C., Klasner, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L. S., Molteni, E., Graham, M. S., Modat, M., Joshi, A. D., ... Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: A prospective observational study. *The Lancet Infectious Diseases*, 21(7), 939–949. [https://doi.org/10.1016/S1473-3099\(21\)00224-3](https://doi.org/10.1016/S1473-3099(21)00224-3)
- Mohamed, N. A., Solehan, H. M., Mohd Rani, M. D., Ithnin, M., & Arujanan, M. (2023). Understanding COVID-19 vaccine hesitancy in Malaysia: Public perception, knowledge, and acceptance. *PLoS One*, 18(4), e0284973.
- Mohammed, R. A., Garout, R. M., Wahid, S., Ayub, F., ZinAlddin, L. M. F., & Sultan, I. (2021). A survey on the side effects of Pfizer/BioNTech COVID-19 vaccine among vaccinated adults in Saudi arabia. *Cureus*, 13(11), e19222. <https://doi.org/10.7759/cureus.19222>
- Morimoto, T., Gandhi, T. K., Seger, A. C., Hsieh, T. C., & Bates, D. W. (2004). Adverse drug events and medication errors: Detection and classification methods. *Quality and Safety in Health Care*, 13(4), 306–314. <https://doi.org/10.1136/qshc.2004.010611>
- Nassar, R. I., Alnatour, D., Thiab, S., Nassar, A., El-Hajji, F., & Basheti, I. A. (2022). Short-term side effects of COVID-19 vaccines: A cross-sectional study in Jordan. *Human Vaccines & Immunotherapeutics*, 18(5), 2082792. <https://doi.org/10.1080/21645515.2022.2082792>
- National Institute of Health Malaysia. (n.d.). *Clinical update on COVID-19*. <https://www.nih.gov.my/covid-19/>.
- Niknam, Z., Jafari, A., Golchin, A., Danesh Pouya, F., Nemati, M., Rezaei-Tavirani, M., & Rasmi, Y. (2022). Potential therapeutic options for COVID-19: An update on current evidence. *European Journal of Medical Research*, 27(1), 6. <https://doi.org/10.1186/s40001-021-00626-3>
- Omeish, H., Najadat, A., Al-Azzam, S., Tarabin, N., Abu Hameed, A., Al-Gallab, N., Abbas, H., Rababah, L., Rabadi, M., Karasneh, R., & Aldeyab, M. A. (2022). Reported COVID-19 vaccines side effects among Jordanian population: A cross sectional study. *Human Vaccines & Immunotherapeutics*, 18(1), 1981086. <https://doi.org/10.1080/21645515.2021.1981086>
- Plotkin, S. A. (2010). Correlates of protection induced by vaccination. *Clinical and Vaccine Immunology*, 17(7), 1055–1065. <https://doi.org/10.1128/CVI.00131-10>
- Potluri, T., Fink, A. L., Sylvia, K. E., Dhakal, S., Vermillion, M. S., vom Steeg, L., Deshpande, S., Narasimhan, H., & Klein, S. L. (2019). Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. *npj Vaccines*, 4(1), 29. <https://doi.org/10.1038/s41541-019-0124-6>
- Pulendran, B. (2014). Systems vaccinology: Probing humanity's diverse immune systems with vaccines. *Proceedings of the National Academy of Sciences of the United States of America*, 111(34), 12300–12306. <https://doi.org/10.1073/pnas.1400476111>
- Razai, M. S., Chaudhry, U. A. R., Doerholt, K., Bauld, L., & Majeed, A. (2021). COVID-19 vaccination hesitancy. *BMJ*, 373, n1138. <https://doi.org/10.1136/bmj.n1138>

- Riad, A., Pokorná, A., Attia, S., Klugarová, J., Koščík, M., & Klugar, M. (2021a). Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech republic. *Journal of Clinical Medicine*, 10(7), 1428. <https://doi.org/10.3390/jcm10071428>
- Riad, A., Sağıroğlu, D., Üstün, B., Pokorná, A., Klugarová, J., Attia, S., ... Klugar, M. (2021b). Prevalence and risk factors of CoronaVac side effects: An independent cross-sectional study among healthcare workers in Turkey. *Journal of Clinical Medicine*, 10(12), 2629. <https://doi.org/10.3390/jcm10122629>
- Saadat, S., Rikhtegaran-Tehrani, Z., Logue, J., Newman, M., Frieman, M. B., Harris, A. D., & Sajadi, M. M. (2021). Single dose vaccination in healthcare workers previously infected with SARS-CoV-2. *MedRxiv*.
- Saeed, B. Q., Al-Shahrabi, R., Alhaj, S. S., Alkokhardi, Z. M., & Adrees, A. O. (2021). Side effects and perceptions following Sinopharm COVID-19 vaccination. *International Journal of Infectious Diseases*, 111, 219–226. <https://doi.org/10.1016/j.ijid.2021.08.013>
- Saeedi, A., Ghaemi, A., Tabarraei, A., Moradi, A., Gorji, A., Semnani, S., Soleimanjahi, H., Adli, A. H., Hosseini, S. Y., & Vakili, M. A. (2014). Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice. *Virus Genes*, 49(1), 11–21. <https://doi.org/10.1007/s11262-014-1070-z>
- Saied, S. M., Saied, E. M., Kabbash, I. A., & Abdo, S. A. E. F. (2021). Vaccine hesitancy: Beliefs and barriers associated with COVID-19 vaccination among Egyptian medical students. *Journal of Medical Virology*, 93(7), 4280–4291. <https://doi.org/10.1002/jmv.26910>
- Shekhar, R., Sheikh, A. B., Upadhyay, S., Singh, M., Kottewar, S., Mir, H., Barrett, E., & Pal, S. (2021). COVID-19 vaccine acceptance among health care workers in the United States. *Vaccines*, 9(2), 119. <https://doi.org/10.3390/vaccines9020119>
- Statista Research Department. (2022). Number of adults in Malaysia from 2012 to 2021. Statistical Package for the Social Sciences (SPSS) version 25.0. (2020).
- Taherdoost, H. (2016, August 10). Validity and reliability of the research instrument; how to test the validation of a questionnaire/survey in a research. *How to test the validation of a questionnaire/survey in a research*.
- Tang, K. H. D. (2021). From movement control to national recovery plan: Malaysia's strategy to live with COVID-19. *International Journal of Science and Healthcare Research*, 6(4), 286–292. <https://doi.org/10.52403/ijshr.20211040>
- Van Grootheest, K., & de Jong-van den Berg, L. (2004). Patients' role in reporting adverse drug reactions. *Expert Opinion on Drug Safety*, 3(4), 363–368. <https://doi.org/10.1517/14740338.3.4.363>
- Vogel, G. (2021). *Mixing vaccines may boost immune responses*. American Association for the Advancement of Science.
- Wang, S., Parker, C., Taaffe, J., Solórzano, A., García-Sastre, A., & Lu, S. (2008). Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. *Vaccine*, 26(29–30), 3626–3633. <https://doi.org/10.1016/j.vaccine.2008.04.073>
- Wise, J. (2021). *COVID-19: People who have had infection might only need one dose of mRNA vaccine*. British Medical Journal Publishing Group.
- Yamane, T. (1967). *A simplified formula to calculate sample size*. Google Scholar.
- Zainul, H. (2021, June 27). As Malaysia's Covid-19 vaccination drive revs up, sceptics threaten to spoil the party.

- Zhai, S., Zhang, Z., Liao, J., & Cui, X. (2023). Learning from real world data about combinatorial treatment selection for COVID-19. *Frontiers in Artificial Intelligence*, 6, 1123285. <https://doi.org/10.3389/frai.2023.1123285>
- Zhang, M.-X., Zhang, T.-T., Shi, G.-F., Cheng, F.-M., Zheng, Y.-M., Tung, T.-H., & Chen, H.-X. (2021). Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. *Expert Review of Vaccines*, 20(7), 891–898. <https://doi.org/10.1080/14760584.2021.1925112>